SCHEMBL12430723

SCHEMBL12430723

COc1ccc(Nc2nc(Nc3cc(C)[nH]n3)c3ccccc3n2)cc1-c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AURKA O14965 9/20 0.69
SRC P12931 6/20 0.69
GSK3B P49841 5/20 0.69
AURKB Q96GD4 5/20 0.58
EIF2AK2 P19525 1/20 0.58
GSK3A P49840 1/20 0.58
NTRK1 P04629 9/20 0.55
INSR P06213 2/20 0.55
IGF1R P08069 2/20 0.55
EPHB4 P54760 2/20 0.55
EGFR P00533 1/20 0.55
PDGFRB P09619 1/20 0.55
FLT4 P35916 1/20 0.55
KDR P35968 1/20 0.55
TEK Q02763 1/20 0.55
NTRK3 Q16288 1/20 0.53
NTRK2 Q16620 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2202716 0.85 ABCG2 (0.49) AURKASRCGSK3B
SCHEMBL7107704 0.83 AURKA (0.83) AURKASRCGSK3BAURKBEIF2AK2
SCHEMBL12430654 0.82 AURKA (1.00) AURKASRCGSK3BAURKBEIF2AK2
SCHEMBL12430719 0.82 AURKA (0.78) AURKASRCGSK3BAURKBEIF2AK2
SCHEMBL12430716 0.81 AURKA (0.80) AURKASRCGSK3BAURKBEIF2AK2
SCHEMBL12510631 0.81 AURKA (0.88) AURKASRCGSK3BAURKBEIF2AK2
SCHEMBL12430733 0.79 AURKA (0.84) AURKASRCGSK3BAURKBEIF2AK2
SCHEMBL12430732 0.79 AURKA (0.84) AURKASRCGSK3BAURKBEIF2AK2
SCHEMBL12430710 0.79 AURKA (0.84) AURKASRCGSK3BAURKBEIF2AK2
SCHEMBL12430661 0.79 AURKA (0.84) AURKASRCGSK3BAURKBEIF2AK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA AURKA 3/4885SRC 298/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.